GO
Loading...

GlaxoSmithKline PLC

More

  • GlaxoSmithKline said it had agreed to buy biotechnology company Sirtris Pharmaceuticals for $720 million in cash, in hopes its medicines that modulate an aging-related family of enzymes will be effective against a wide range of diseases.

  • Halftime Report: Da Bears Are Winning Tuesday, 22 Apr 2008 | 12:41 PM ET

    This halftime report is not brought to you by (pick your prescription drug). So, we're pretty much at the midway point of big pharma's earnings season and Goldman Sachs analyst James Kelly is sizing things up so far...

  • Clank of America Monday, 21 Apr 2008 | 6:17 PM ET

    The Dow pulled back Monday after a weaker-than-expected profit report from Bank of America stirred concerns about the health of corporate earnings. What's the "Word on The Street?"

  • Springtime for Pharma: A Big Week Ahead For Earnings Friday, 18 Apr 2008 | 12:01 PM ET

    The irreverent producers of "Squawk on the Street" who are stationed in the pod next to mine here at CNBC like to call it "Pharmapalooza." They're referring to weeks like the one coming up when nearly every big drug company reports earnings.

  • Roche Misses First-Quarter Profit Forecast Thursday, 17 Apr 2008 | 12:13 PM ET
    Tamiflu Tabletten, fotografiert am Mittwoch, 15. Maerz 2006 in Frankfurt am Main. (AP Photo/Michael Probst) ---Tamiflu pills in Frankfurt, central Germany, Wednesday, March 15, 2006. (AP Photo/Michael Probst)

    Roche Holding missed forecasts with a meagre 2 percent increase in first-quarter sales in local currencies, hit by plunging Tamiflu revenue and a slowing pace of growth for cancer drugs.

  • Glaxo, Pozen Become "Headache Free" On Migraine Drug Wednesday, 16 Apr 2008 | 11:21 AM ET

    After navigating what has to be one of the most frustrating paths to Food and Drug Administration approval of a new drug, the small biopharma company Pozen and its big pharma partner GlaxoSmithKline have finally emerged victorious.

  • Genentech Earnings Preview: Cure for Portfolio Ills? Thursday, 10 Apr 2008 | 1:37 PM ET
    Genetech

    Genentech stock is on a tear this year and analysts are expecting double-digit sales growth for most of the biotech's key drugs this quarter. Can Genentech keep it up?

  • Pfizer's Viagra

    Last night while on the elliptical and watching "NBC Nightly News," one spot amid the wall-to-wall commercials for drugs caught my attention. It looks like after 10 years since the first erectile dysfunction pill came on the market--Pfizer's Viagra celebrated a decade since winning FDA approval last week--the makers of Levitra are trying a new marketing tack.

  • Panel: AIDS Drug Doubles Heart Attack Risk Tuesday, 1 Apr 2008 | 4:59 PM ET

    A drug commonly used to fight AIDS appears to nearly double the risk of a heart attack, researchers said Tuesday.

  • Biovail's Travails And The "Haunting" Truck Accident Monday, 24 Mar 2008 | 4:12 PM ET
    BIOVAIL

    Shares of Canada's biggest biotech initially hit a new intra-day low this morning of 10 bucks a share this morning, but rallied into the close as investors seem to like the fact that the company may have extricated itself from allegations of financial fraud.

  • Merck And Big Pharma: Both Getting A Stock "Booster" Shot? Wednesday, 19 Mar 2008 | 11:14 AM ET
    Gardasil

    Merck this morning announced that it has filed for Food and Drug Administration approval of its blockbuster cervical cancer vaccine, Gardasil, for women 27-45 years old. Right now it's approved for females 9-26.

  • Lightning Round: Wachovia, Crocs, Ford and More Tuesday, 18 Mar 2008 | 7:03 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Lightning Round: Altria, Delta, VMware and More Wednesday, 12 Mar 2008 | 7:29 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Big Pharma: Market Medicine? Monday, 3 Mar 2008 | 4:06 PM ET

    With Warren Buffett nosing around Big Pharma, investors are starting to wonder if drug makers might be the remedy to what ails this market.

  • In a series of exclusive live appearances on CNBC's Squawk Box this morning, Warren Buffett told us that by a "common sense definition", the U.S. economy is already in a recession, even if it hasn't met the technical definition of two consecutive quarters of negative growth.  He restated, however, his view that over the long-run the U.S. economy will do fine and that each generation will live better than the one before it.

  • Glaxo Wins FDA Priority Review for Blood Drug Monday, 3 Mar 2008 | 11:04 AM ET

    GlaxoSmithKline's experimental platelet-boosting drug Promacta has been granted priority review by U.S. health regulators, boosting prospects for its early launch, Europe's biggest drugmaker said on Monday.

  • Drug Money Still A "Healthy Flow" To Democrats Monday, 3 Mar 2008 | 9:29 AM ET

    On the eve of the make-or-break Texas-Ohio primaries for Sen. Hillary Clinton, she remains in first place in at least one "poll." The Center for Responsive Politics has updated its list of top pharmaceuticals/health products-industry money recipients based on the most recent campaign finance reports and the former First Lady edges out Sen. Barack Obama...

  • Glaxo's Tykerb Goes Head-to-Head with Herceptin Friday, 29 Feb 2008 | 5:10 AM ET

    GlaxoSmithKline's new breast cancer drug Tykerb is to go head-to-head with Genentech's blockbuster Herceptin to see whether one is better or if patients should get both.

  • Boxes of Kraft Macaroni and Cheese are seen Wednesday, April 19, 2006, in Milwaukee. Kraft Foods Inc. releases first-quarter earnings after the bell.  (AP Photo/Morry Gash)

    Warren Buffett's Berkshire Hathaway has accumulated an 8.6% stake in Kraft Foods, totaling over 132 million shares as of the end of the fourth quarter on December 31. That stake was worth $4.3 billion at that time. At today's closing price of $29.31, it's worth about $3.9 billion.  EXPLORE WARREN BUFFETT'S INVESTMENTS WITH OUR NEW BERKSHIRE HATHAWAY PORTFOLIO TRACKER

  • Market Insider/Friday Look Ahead  Thursday, 14 Feb 2008 | 8:24 PM ET

    Friday's markets will likely continue to be vulnerable to credit worries. There are a few economic data points including import prices and the Empire State survey, both at 8:30 a.m. TIC data from the Treasury is released at 9 a.m. and industrial production comes out at 8:15 a.m. Consumer sentiment is due at 10 a.m.